Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
This activity is supported by an educational grant from AstraZeneca.
Do biological agents improve health-related quality of life in patients with systemic lupus erythematosus? Results from a systematic search of the literature
Autoimmun Rev. 2022 doi: 10.1016/j.autrev.2022.103188
Gomez, et al. summarise the effects of biological therapies on SLE patients' health-related quality of life (HRQoL) in RCT and real-life settings, based on a systematic search of the literature.
Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumab
Lancet Rheumatol 2022;4:e198–207
In patients with moderate-to-severe SLE, British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) responders report improvements in disease activity, health-related quality of life, fatigue, and pain.
Real-world Impact of Flaring on Patient-Reported Outcomes and Healthcare Resource Utilisation in Systemic Lupus Erythematosus
Clin Exp Rheumatol. 2021.Epub ahead of print
Data from the real world underscores the need for more effective strategies and treatments to alleviate or prevent flaring in systemic lupus erythematosus (SLE).
Despite data from Hong Kong and Canada showing an association of flaring with reduced health-related quality of life and increased healthcare resourse utilisation and costs, similar international data are limited.